請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53556
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 周綠蘋 | |
dc.contributor.author | Hsin-Hua Yang | en |
dc.contributor.author | 楊欣樺 | zh_TW |
dc.date.accessioned | 2021-06-16T02:25:41Z | - |
dc.date.available | 2025-12-31 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-06 | |
dc.identifier.citation | 1. Carrato, A., Falcone, A., Ducreux, M., Valle, J. W., Parnaby, A., Djazouli, K., Alnwick-Allu, K., Hutchings, A., Palaska, C., and Parthenaki, I. (2015) A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. Journal of gastrointestinal cancer 2. Parkin, D. M., Bray, F. I., and Devesa, S. S. (2001) Cancer burden in the year 2000. The global picture. European journal of cancer 37 Suppl 8, S4-66 3. Katanoda, K., and Dongmei, Q. (2008) Comparison of time trends in pancreatic cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII. Japanese journal of clinical oncology 38, 165-166 4. Ma, J., Siegel, R., and Jemal, A. (2013) Pancreatic cancer death rates by race among US men and women, 1970-2009. Journal of the National Cancer Institute 105, 1694-1700 5. Huxley, R., Ansary-Moghaddam, A., Berrington de Gonzalez, A., Barzi, F., and Woodward, M. (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British journal of cancer 92, 2076-2083 6. Toriola, A. T., Stolzenberg-Solomon, R., Dalidowitz, L., Linehan, D., and Colditz, G. (2014) Diabetes and pancreatic cancer survival: a prospective cohort-based study. British journal of cancer 111, 181-185 7. Mizuno, S., Nakai, Y., Isayama, H., Kawahata, S., Saito, T., Takagi, K., Watanabe, T., Uchino, R., Hamada, T., Miyabayashi, K., Kogure, H., Sasaki, T., Yamamoto, N., Sasahira, N., Hirano, K., Tsujino, T., Ijichi, H., Tateishi, K., Tada, M., and Koike, K. (2014) Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Pancreas 43, 1014-1017 8. Iodice, S., Gandini, S., Maisonneuve, P., and Lowenfels, A. B. (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 393, 535-545 9. Maisonneuve, P., and Lowenfels, A. B. (2015) Risk factors for pancreatic cancer: a summary review of meta-analytical studies. International journal of epidemiology 44, 186-198 10. Liao, W. C., Tu, Y. K., Wu, M. S., Lin, J. T., Wang, H. P., and Chien, K. L. (2015) Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. Bmj 349, g7371 11. Gullo, L., Ancona, D., Pezzilli, R., Casadei, R., and Campione, O. (1993) Glucose tolerance and insulin secretion in pancreatic cancer. The Italian journal of gastroenterology 25, 487-489 12. Toriola, A. T., and Fields, R. C. (2014) Inflammatory, insulin resistance metabolic markers and pancreatic cancer: quo vadis? [corrected]. Future oncology 10, 1519-1522 13. De Souza, A. L., and Saif, M. W. (2014) Diabetes and pancreatic cancer. JOP : Journal of the pancreas 15, 118-120 14. Patel, R., Ede, J., Collins, J., and Willens, D. (2014) Pancreatic cancer presenting as new-onset diabetes. Case reports in oncology 7, 171-174 15. Tantau, A., Negrean, V., Alexescu, T., Para, I., Tarmure, S., Casoinic, F., Sampelean, D., Mocanu, T., and Tantau, M. (2014) Two different types of diabetes mellitus in pancreatic cancer population. Comparative study between new onset and long standing diabetes mellitus on 76 patients with pancreatic cancer. Romanian journal of internal medicine = Revue roumaine de medecine interne 52, 18-23 16. Chari, S. T., Leibson, C. L., Rabe, K. G., Timmons, L. J., Ransom, J., de Andrade, M., and Petersen, G. M. (2008) Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134, 95-101 17. Pannala, R., Basu, A., Petersen, G. M., and Chari, S. T. (2009) New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. The Lancet. Oncology 10, 88-95 18. Wilkins, M. R., Appel, R. D., Van Eyk, J. E., Chung, M. C., Gorg, A., Hecker, M., Huber, L. A., Langen, H., Link, A. J., Paik, Y. K., Patterson, S. D., Pennington, S. R., Rabilloud, T., Simpson, R. J., Weiss, W., and Dunn, M. J. (2006) Guidelines for the next 10 years of proteomics. Proteomics 6, 4-8 19. Picotti, P., Aebersold, R., and Domon, B. (2007) The implications of proteolytic background for shotgun proteomics. Molecular cellular proteomics : MCP 6, 1589-1598 20. Lee, I. N., Chen, C. H., Sheu, J. C., Lee, H. S., Huang, G. T., Chen, D. S., Yu, C. Y., Wen, C. L., Lu, F. J., and Chow, L. P. (2006) Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6, 2865-2873 21. Lee, I. N., Chen, C. H., Sheu, J. C., Lee, H. S., Huang, G. T., Yu, C. Y., Lu, F. J., and Chow, L. P. (2005) Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. Journal of proteome research 4, 2062-2069 22. O'Brien, D. P., Sandanayake, N. S., Jenkinson, C., Gentry-Maharaj, A., Apostolidou, S., Fourkala, E. O., Camuzeaux, S., Blyuss, O., Gunu, R., Dawnay, A., Zaikin, A., Smith, R. C., Jacobs, I. J., Menon, U., Costello, E., Pereira, S. P., and Timms, J. F. (2015) Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clinical cancer research : an official journal of the American Association for Cancer Research 21, 622-631 23. Massuti, B., Sanchez, J. M., Hernando-Trancho, F., Karachaliou, N., and Rosell, R. (2013) Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Translational lung cancer research 2, 208-221 24. Zhang, C., Yang, G., Ling, Y., Chen, G., and Zhou, T. (2014) The early diagnosis of pancreatic cancer and diabetes: what's the relationship? Journal of gastrointestinal oncology 5, 481-488 25. Yamada, K., Saito, M., Matsuoka, H., and Inagaki, N. (2007) A real-time method of imaging glucose uptake in single, living mammalian cells. Nature protocols 2, 753-762 26. Antelmann, H., Tjalsma, H., Voigt, B., Ohlmeier, S., Bron, S., van Dijl, J. M., and Hecker, M. (2001) A proteomic view on genome-based signal peptide predictions. Genome research 11, 1484-1502 27. Nagele, E., Vollmer, M., Horth, P., and Vad, C. (2004) 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert review of proteomics 1, 37-46 28. Horvath, K., Fairchild, J., and Guiochon, G. (2009) Optimization strategies for off-line two-dimensional liquid chromatography. Journal of chromatography. A 1216, 2511-2518 29. Chen, C. Y., Chi, L. M., Chi, H. C., Tsai, M. M., Tsai, C. Y., Tseng, Y. H., Lin, Y. H., Chen, W. J., Huang, Y. H., and Lin, K. H. (2012) Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells. Molecular cellular proteomics : MCP 11, M111 011270 30. Yao, L., Zhang, Y., Chen, K., Hu, X., and Xu, L. X. (2011) Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PloS one 6, e24684 31. Karagiannis, G. S., Pavlou, M. P., Saraon, P., Musrap, N., Xie, A., Batruch, I., Prassas, I., Dimitromanolakis, A., Petraki, C., and Diamandis, E. P. (2014) In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers. Journal of proteomics 103, 121-136 32. Chen, Y. H., Chou, H. C., Lin, S. T., Chen, Y. W., Lo, Y. W., and Chan, H. L. (2012) Effect of high glucose on secreted proteome in cultured retinal pigmented epithelium cells: its possible relevance to clinical diabetic retinopathy. Journal of proteomics 77, 111-128 33. Webb, G. C., Akbar, M. S., Zhao, C., and Steiner, D. F. (2000) Expression profiling of pancreatic beta cells: glucose regulation of secretory and metabolic pathway genes. Proceedings of the National Academy of Sciences of the United States of America 97, 5773-5778 34. Song, S., Ji, B., Ramachandran, V., Wang, H., Hafley, M., Logsdon, C., and Bresalier, R. S. (2012) Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PloS one 7, e42699 35. Nangia-Makker, P., Honjo, Y., Sarvis, R., Akahani, S., Hogan, V., Pienta, K. J., and Raz, A. (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. The American journal of pathology 156, 899-909 36. Matarrese, P., Fusco, O., Tinari, N., Natoli, C., Liu, F. T., Semeraro, M. L., Malorni, W., and Iacobelli, S. (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. International journal of cancer. Journal international du cancer 85, 545-554 37. Pricci, F., Leto, G., Amadio, L., Iacobini, C., Romeo, G., Cordone, S., Gradini, R., Barsotti, P., Liu, F. T., Di Mario, U., and Pugliese, G. (2000) Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney international. Supplement 77, S31-39 38. Shoelson, S. E., Lee, J., and Goldfine, A. B. (2006) Inflammation and insulin resistance. The Journal of clinical investigation 116, 1793-1801 39. Greenfield, J. R., and Campbell, L. V. (2006) Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'? Current diabetes reviews 2, 195-211 40. Dumic, J., Lauc, G., and Flogel, M. (2000) Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 10, 149-158 41. Kim, K., Mayer, E. P., and Nachtigal, M. (2003) Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochimica et biophysica acta 1641, 13-23 42. Zeng, Y., Danielson, K. G., Albert, T. J., Shapiro, I. M., and Risbud, M. V. (2007) HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 22, 1851-1861 43. Raimond, J., Rouleux, F., Monsigny, M., and Legrand, A. (1995) The second intron of the human galectin-3 gene has a strong promoter activity down-regulated by p53. FEBS letters 363, 165-169 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53556 | - |
dc.description.abstract | 胰臟癌是世界上致死率最高的癌症之一,其五年內存活率不到百分之五,目前大部份胰臟癌治療方式為手術切除,然而約85%的病人就診時已是胰臟癌晚期,無法適用手術切除腫瘤,因此目前急需要有效的早期診斷方法如生物標記,來幫助早期胰臟癌之診斷。據統計約有40%的胰臟癌病人,在胰臟癌前兩年伴隨著新生糖尿病的現象,新生糖尿病發生的時間為我們提供一個絕佳早期診斷胰臟癌的機會,新生糖尿病是由於胰臟癌細胞分泌某些致糖尿病因子 (diabetogenic factors)所造成。目前形成的機制仍未知,但如果我們可以找到這些致糖尿病因子,除了可以幫助我們釐清其機轉,作為生物標記也可為我們區分新生糖尿病和第二型糖尿病患者,達到早期診斷胰臟癌的目的。 我們收集了兩種胰臟癌細胞MIAPaCa-2和PANC-1的分泌性蛋白,經濃縮去鹽後以LC-MS/MS鑑定,將結果以Ingenuity Pathway Analysis (IPA)將蛋白依相關疾病、生理現象和功能分類後,與胰臟癌病人表現量較高之基因互相交集比較,以IPA分析有潛力成為致糖尿病因子,並觀察到候選蛋白在高糖環境下MIAPaCa-2的分泌量上升,即選定galectin-1和galectin-3為目標蛋白。接著以分泌性蛋白、galectin-1、galectin-3分別和老鼠肌肉細胞進行培養,發現皆會影響其葡萄糖攝取能力,干擾肌肉細胞的胰島素敏感程度。而在病人檢體中,可以看到galectin-1含量在新生糖尿病、糖尿病、胰臟癌病人、健康人檢體中分佈平均,無法將病人做區隔,因此不能作為有效的生物。反觀galectin-3在病人檢體中含量有顯著差別,可以將病人區隔成新生糖尿病、糖尿病與胰臟癌、健康人兩組。而為了知道這些目標蛋白如何影響胰島素之傳遞,我們觀察在有目標蛋白存在時,胰島素訊息傳遞路徑是否有受到抑制,發現IRS-1和Akt的磷酸化皆明顯減弱。倘若繼續找到其他糖尿病或新生糖尿病生物標記,則可以將四群病人完全分開,以複合型生物標記形式可有效達到胰臟癌的早期診斷,並供後續研究致糖尿病因子的發展機轉。 | zh_TW |
dc.description.abstract | Pancreatic Cancer (PC) is one of the leading cause of cancer death in the world with a 5-year survival less than 5%. Surgical resection of tumor is the only potential therapy, but the PC-specific symptoms occur late and 85% of the tumors are diagnosed when a surgical cure is impossible. Thus, the discovery of biomarkers for early detection is urgent necessary. There are approximately 40% of PC patients followed with PC-associated new-onset diabetes (PCDM), occurring 2 years before the tumor is diagnosed, which provides a potential opportunity to detect PC in early stages. PCDM is mediated by some unknown tumor-secreted diabetogenic factors. Identifying the diabetogenic factors may provide novel insights into its pathogenesis and discover a novel biomarker to distinguish PCDM from type 2 diabetes (T2DM). To discover the diabetogenic factors and potential serum PC biomarkers, we collected the condition medium (CM) from two PC cell lines (MIAPaCa-2 and PANC-1). Potential factors in CM further identified by gel-based LC-MS/MS and analyzed by Ingenuity Pathway Analysis (IPA). We also found some candidate proteins, which were up-regulated in PC patients from microarray analysis. Comparison of data in proteomics and microarray, we found the secretion proteins of target (galectin-1 and galectin-3) from MIPaCa-2 under high glucose condition were increased. The glucose uptake was reduced in C2C12 mouse skeletal muscle cells under the incubation with CM, galectin-1 or galectin-3. For clinical validation of the potential biomarkers, we confirmed the levels of galectin-1 and galectin-3 among patients of PC, diabetes, and healthy controls. The data revealed only galectin-3 can distinguish patients of PCDM and T2DM from PC and healthy controls. To verify how the factors affect glucose uptake by regulating insulin signaling, we observed the phosphorylation levels of insulin receptor substrate-1 (p-IRS-1) and Akt by Western blotting after treated C2C12 with CM, galectin-1 or galectin-3. Our results shown both p-IRS-1 and p-Akt were attenuated. Other target proteins in our finding are also potential candidates for diabetogenic factors. We will construct these potential biomarkers into a multiple biomarker panel, and look forward to using as early diagnosis tool for PC. Identification of diabetogenic factors is necessary not only for early detection of PC, but also for clarifying the mechanism of PC associated new-onset diabetes. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:25:41Z (GMT). No. of bitstreams: 1 ntu-104-R02442025-1.pdf: 4068328 bytes, checksum: 03256c54c12e2657843b5667c36e6230 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口委意見書 I 謝誌 II 中文摘要 III ABSTRACT IV 縮寫 VI 目錄 VIII 第一節 胰臟癌 1 1.1 胰臟癌之流行病學 1 1.2 胰臟癌的危險因子 1 1.3 胰臟癌的診斷與治療 2 1.4 胰臟癌與高血糖現象的關係 2 1.5 胰臟癌與胰島素阻抗現象之關係 3 第二節 新生糖尿病 3 2.1 新生糖尿病的定義 3 2.2 新生糖尿病的潛在應用性 3 第三節 蛋白質體學 4 5.1 蛋白質體學定義 4 5.2 蛋白質體學在癌症生物標記研究上的應用 4 第四節 生物標記 4 6.1 生物標記的定義 4 6.2 腫瘤生物標記 5 6.3 新生糖尿病生物標記 6 第五節 研究動機 6 第一節 細胞株 7 1.1 人類胰臟癌細胞株 7 1.2 老鼠肌肉細胞株 7 第二節 血清樣本 7 第三節 抗體 7 第四節 藥品 8 第五節 試劑組 10 第六節 重要儀器 10 第七節 酵素 11 第八節 軟體及資料庫 11 第三章 實驗方法 12 第一節 胰臟癌細胞的培養 12 1.1 細胞的培養 (Cell culture) 12 1.2 細胞的計數與細胞的存活率 (Cell counting and cell viability) 12 第二節 蛋白質分析法 12 2.1 蛋白質濃度測定 (BCA protein assay) 12 2.2 十二烷基磺酸鈉-聚丙醯胺凝膠電泳法 (SDS-PAGE) 13 2.3 電泳膠體的染色 (Protein staining) 15 2.4 西方點墨法 (Western blot) 17 第三節 胰臟癌細胞分泌蛋白的收集 19 第四節 胰臟癌細胞株分泌體之蛋白鑑定 19 4.1 膠體內水解 (In-gel digestion) 19 4.2 溶液中水解 (In-solution digestion) 20 4.3 液相層析偶合串聯式質譜儀分析 (NanoLC-MS/MS analysis) 21 4.4 生物資訊 (Bioimformation) 22 第五節 肌肉細胞葡萄糖攝取之測定 (2-NBDG UPTAKE ASSAY) 23 第六節 候選蛋白之製備 (CANDIDATE PROTEIN PREPARATION) 24 6.1 候選蛋白之質體建構 24 6.2 候選蛋白之表現 24 6.3 候選蛋白之純化 24 第七節 訊息傳遞的研究 25 7.1 細胞添加蛋白處理 (Protein treatment) 25 7.2 裂解細胞 (Cell lysis) 25 7.3 細胞裂解液的配置 (Preparation of RIPA cell lysis buffer) 25 第八節 血清中蛋白質濃度測定 26 8.1 酵素連結免疫吸附法 (Enzyme-link immunosorbent assay,ELISA) 26 8.2 Diluent buffer的配置 (Preparation of diliuent buffer) 26 第四章 實驗結果 27 第一節 生物資訊之收集與分析 27 1.1 胰臟癌病人對健康人cDNA microarray分析結果之資訊取得與分析 27 1.2 MIAPaCa-2與PANC-1細胞之分泌性蛋白鑑定與分析 27 1.3 胰臟癌組織表現量上升基因與胰臟癌細胞分泌性蛋白體之比較 27 1.4 MIAPaCa-2細胞於不同糖濃度環境下之候選蛋白表現量差異 28 第二節 致糖尿病因子造成胰島素阻抗現象之功能探討 28 2.1 MIAPaCa-2和PANC-1細胞之分泌性蛋白對葡萄糖攝取能力之影響 28 2.2 依分子量大小分離之分泌性蛋白對葡萄糖攝取能力之影響 28 2.3 候選蛋白galectin-1和galectin-3對葡萄糖攝取能力之影響 29 第三節 臨床檢體之驗證 29 3.1 不同族群病人與健康人血液中galectin-1含量 29 3.2 不同族群病人與健康人血液中galectin-3含量 29 第四節 GALECTIN-1與GALECTIN-3調控之訊息傳遞路徑 30 第五節 結論 30 第五章 討論 32 第一節 蛋白質體學與生物資訊的應用 32 第二節 候選分子的選擇 33 第三節 半乳糖凝集素 (GALECTIN FAMILY)之種類、功能與調控 34 第四節 複合型生物標記與個人化醫療趨勢 36 第六章 參考文獻 38 圖 43 FIGURE 1 | THE SCHEMATIC DIAGRAM FOR IDENTIFICATION OF POTENTIAL DIABETOGENIC FACTORS. 44 FIGURE 2 | SPECTRA OF POTENTIAL TARGETS IDENTIFIED BY LC-MS/MS. 45 FIGURE 3 | CANDIDATE PROTEIN EXPRESSION PATTERN BY MIAPACA-2 CHANGES IN DIFFERENT CONCENTRATION OF GLUCOSE. 46 FIGURE 4 | EFFECT OF CM FROM DIFFERENT PC CELL LINES ON GLUCOSE UPTAKE ABILITY IN C2C12 CELLS. 47 FIGURE 5 | EFFECT OF FRACTIONATED CM FROM PANCREATIC CANCER CELL LINES ON 2-NBDG GLUCOSE UPTAKE ABILITY IN C2C12. 48 FIGURE 6 | CANDIDATE PROTEIN PREPARATION. 49 FIGURE 7 | EFFECTS OF POTENTIAL TARGETS ON GLUCOSE UPTAKE IN C2C12 CELLS. 50 FIGURE 8 | THE CORRELATION OF GALECTIN-1 AND GALECTIN-3 WITH NEW-ONSET DIABETES. 51 FIGURE 9 | C2C12 DOWNSTREAM SIGNALING INFLUENCED BY CM AND DIABETOGENIC FACTORS. 52 表 53 TABLE 1 | BIO-FUNCTIONAL ANALYSIS OF THE UP-REGULATED GENE IN PC TISSUE COMPARE TO HEALTHY CONTROLS BY IPA. 54 TABLE 2 | BIO-FUNCTIONAL ANALYSIS OF MIAPACA-2 CONDITIONED MEDIUM BY IPA. 55 TABLE 3 | BIO-FUNCTIONAL ANALYSIS OF PANC-1 CONDITIONED MEDIUM BY IPA. 56 TABLE 4 | BIO-FUNCTIONAL ANALYSIS OF COMPARISON RESULTS OF MICROARRAY AND PROTEOMICS DATA BY IPA. 57 APPENDIX 58 APPENDIX 1 | LIST OF UP-REGULATED GENES IN PC TISSUES COMPARE TO HEALTHY CONTROLS. 59 APPENDIX 2 | LIST OF MIAPACA-2 CONDITIONED MEDIUM SECRETOME. 74 APPENDIX 3 | LIST OF PANC-1 CONDITIONED MEDIUM SECRETOME. 140 APPENDIX 4 | CLINICAL INFORMATION OF PATIENTS. 177 | |
dc.language.iso | zh-TW | |
dc.title | 鑑定胰臟癌誘發新生糖尿病之致糖尿病因子 | zh_TW |
dc.title | Identification of Diabetogenic Factors in Pancreatic Cancer-associated New-Onset Diabetes | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳明賢,廖偉智 | |
dc.subject.keyword | 胰臟癌,新生糖尿病,生物標記,半乳糖凝集素,分泌性蛋白, | zh_TW |
dc.subject.keyword | Pancreatic Cancer,new-onset diabetes,biomarker,galectin-3,secretome., | en |
dc.relation.page | 180 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-06 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 3.97 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。